Merck’s (MRK) WINREVAIR Shows Strong Results in HYPERION Trial
Merck & Co., Inc. (NYSE:MRK) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company shared encouraging results from its Phase 3 HYPERION trial.
Merck & Co. Inc. (MRK)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Fisher Asset Management Ken Fisher | 24,445,797 | $2,194,254,812 | +52% | 0.95% |
| 2. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 14,362,008 | $1,289,133,838 | +122% | 1.05% |
| 3. | D E Shaw D. E. Shaw | 9,311,726 | $835,820,526 | +47% | 0.74% |
| 4. | AQR Capital Management Cliff Asness | 7,757,818 | $691,066,492 | +45% | 0.71% |
| 5. | Harris Associates Natixis Global Asset Management | 7,469,360 | $670,449,735 | +20% | 1.13% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $88.25 | 2,833 | $249,999.98 | 2,933 | 2025-02-06 | Filing | |
| $88.50 | 15,000 | $1,327,500.00 | 16,000 | 2025-02-05 | Filing | |
| $113.68 | 3 | $341.04 | 20,599 | 2023-04-26 | Filing | |
| $105.47 | 136 | $14,343.92 | 20,631 | 2023-03-20 | Filing | |
| $109.20 | 11 | $1,201.20 | 20,495 | 2023-02-21 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $82.76 | 4,262 | $352,723.12 | 7,778 | 2025-04-25 | Filing | |
| $84.09 | 8,500 | $714,744.60 | 30,705 | 2025-02-19 | Filing | |
| $85.34 | 6,000 | $512,056.80 | 24,123 | 2025-02-13 | Filing | |
| $88.76 | 2,361 | $209,550.79 | 7,085 | 2025-02-06 | Filing | |
| $125.50 | 38,291 | $4,805,520.50 | 50,908 | 2024-02-14 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 252,513,381 | $22,665,601,078 | 0.41% | |
| 2. | 225,398,231 | $20,231,745,187 | 0.42% | |
| 3. | 120,529,640 | $10,914,833,116 | 0.45% | |
| 4. | 81,669,651 | $7,330,667,874 | 1.41% | |
| 5. | 59,657,270 | $5,343,873,419 | 0.42% |
News See All
Should You Count on MRK for Steady Passive Income?
Merck & Co., Inc. (NYSE:MRK) is a leading pharmaceutical company, best known for its strong presence in oncology, particularly through Keytruda, the top-selling drug globally.
12 Stocks That Will Make You Rich in 10 Years
One of the most read (and recommended) books on investing is Benjamin Graham’s The Intelligent Investor. Among many others, long-term investing is a foundational theme in the book.
10 Best Stocks to Buy For Dividends
Over the past two years, dividend stocks have lagged behind the broader market as investor interest shifted toward companies focused on artificial intelligence.
Jefferies Maintains a Buy Rating on Merck & Co. (MRK), Keeps the PT Unchanged
Merck & Co., Inc. (NYSE:MRK) is one of the 10 Best and Cheap Stocks to Buy Now. On June 18, Akash Tewari, an analyst from Jefferies, maintained the Buy rating on Merck & Co., Inc.
Jefferies Reaffirms Merck (MRK) ‘Buy’ Rating on Gardasil Dosing Stability
Merck & Co., Inc. (NYSE:MRK) is another biopharmaceutical company on the list of the 10 undervalued blue chip stocks analysts recommend for smart investing.
10 Best and Cheap Stocks to Buy Now
On June 4 Morningstar released its June 2025 outlook, indicating that as of May 30, the US stock market was trading at a 3% discount to its fair value.
10 Best Dividend Leaders to Buy Now
Investors have long favored dividend stocks for their financial strength and solid returns, which have historically outpaced many other asset classes.
10 Undervalued Blue Chip Stocks Analysts Recommend for Smart Investing
Blue-chip stocks are great assets for investors looking for opportunities to grow their capital in the long term. Some call them steady oaks in the forest of finance.
Billionaire Hedge Funds
